

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2022/261250 A8

(43) International Publication Date
15 December 2022 (15.12.2022)

WIPO | PCT

(51) International Patent Classification:

A61K 31/517 (2006.01) C07D 403/14 (2006.01)
C07D 239/88 (2006.01) A61P 35/00 (2006.01)
C07D 401/14 (2006.01)

(72) Inventors: NASVESCHUK, Christopher, G.; C/o C4

Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). JACKSON, Katrina, L.; C/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). LIANG, Yanke; C/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). YU, Robert, T.; C/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). DUPLESSIS, Martin; C/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). FITZGERALD, Mark, E.; C/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). GARZA, Victoria; C/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). GOOD, Andrew, Charles; C/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). O'SHEA, Morgan, Welzel; C/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). VEITS, Gesine, Kerstin; C/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). DOLENTE, Cosimo; C/o F. Hoffmann-la Roche Ag, Grenzacherstrasse 124, 4070 Basel (CH). HEWING, David, Stephen; C/o F.

(21) International Application Number:

PCT/US2022/032729

(22) International Filing Date:

08 June 2022 (08.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21178150.5	08 June 2021 (08.06.2021)	EP
21178152.1	08 June 2021 (08.06.2021)	EP
21178145.5	08 June 2021 (08.06.2021)	EP
63/277,973	10 November 2021 (10.11.2021)	US

(71) Applicant: C4 THERAPEUTICS, INC. [US/US]; 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US).

(54) Title: THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF




FIG. 14

(57) Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

[Continued on next page]

Hoffmann-la Roche Ag, Grenzacherstrasse 124, 4070 Basel (CH). **HUNZIKER, Daniel**; C/o F. Hoffmann-la Roche Ag, Grenzacherstrasse 124, 4070 Basel (CH). **KRUMME-NACHER, Daniela**; C/o F. Hoffmann-la Roche Ag, Grenzacherstrasse 124, 4070 Basel (CH). **PETTAZZONI, Piergiorgio Francesco, Tommaso**; C/o F. Hoffmann-la Roche Ag, Grenzacherstrasse 124, 4070 Basel (CH). **WICHMANN, Juergen**; C/o F. Hoffmann-la Roche Ag, Grenzacherstrasse 124, 4070 Basel (CH).

(74) **Agent: BELLOWS, Brent, R.** et al.; Knowles Intellectual Property Strategie, LLC, 400 Perimeter Center Terrace Suite 200, Atlanta, GA 30346 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(48) **Date of publication of this corrected version:**

23 February 2023 (23.02.2023)

(15) **Information about Correction:**

see Notice of 23 February 2023 (23.02.2023)